Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31628144.
- Also identified by DOI 10.1158/1078-0432.CCR-19-2926 and PMC identifier 6942627.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments. A glycolytic subtype indicates poor survival in patients with pancreatic cancer, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Personalized medicine holds great promise for improving therapy outcomes by optimally targeting metabolic pathways.<i>See related article by Karasinska et al., p. 135</i>.
Medical subject headings
- Glycolysis
- Pancreatic Neoplasms